A Clinical Safety and Efficacy Evaluation of Zylet (Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3% vs. Tobradex (Tobramycin and Dexamethasone Ophthalmic Suspension, 0.3%/0.1%) in the Treatment of Blepharokeratoconjunctivitis.

Trial Profile

A Clinical Safety and Efficacy Evaluation of Zylet (Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3% vs. Tobradex (Tobramycin and Dexamethasone Ophthalmic Suspension, 0.3%/0.1%) in the Treatment of Blepharokeratoconjunctivitis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2013

At a glance

  • Drugs Loteprednol etabonate/tobramycin; Tobramycin/dexamethasone
  • Indications Bacterial infections; Blepharoconjunctivitis; Keratoconjunctivitis; Ocular inflammation
  • Focus Therapeutic Use
  • Sponsors Bausch & Lomb
  • Most Recent Events

    • 27 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top